Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2010 1
2011 3
2012 1
2013 4
2021 2
2022 3
2023 4
2024 3
2025 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

26 results

Results by year

Filters applied: . Clear all
Page 1
Interim 2024/25 influenza vaccine effectiveness: eight European studies, September 2024 to January 2025.
Rose AM, Lucaccioni H, Marsh K, Kirsebom F, Whitaker H, Emborg HD, Bolt Botnen A, O'Doherty MG, Pozo F, Hameed SS, Andrews N, Hamilton M, Trebbien R, Lauenborg Møller K, Marques DF, Murphy S, McQueenie R, Lopez-Bernal J, Cottrell S, Bucholc M, Kissling E; European IVE group; Members of the European IVE group. Rose AM, et al. Euro Surveill. 2025 Feb;30(7):2500102. doi: 10.2807/1560-7917.ES.2025.30.7.2500102. Euro Surveill. 2025. PMID: 39980423 Free PMC article.
Effectiveness of the XBB.1.5 COVID-19 Vaccines Against SARS-CoV-2 Hospitalisation Among Adults Aged ≥ 65 Years During the BA.2.86/JN.1 Predominant Period, VEBIS Hospital Study, Europe, November 2023 to May 2024.
Antunes L, Rojas-Castro M, Lozano M, Martínez-Baz I, Leroux-Roels I, Borg ML, Oroszi B, Fitzgerald M, Dürrwald R, Jancoriene L, Machado A, Petrović G, Lazar M, Součková L, Bacci S, Howard J, Verdasca N, Basile L, Castilla J, Ternest S, Džiugytė A, Túri G, Duffy R, Hackmann C, Kuliese M, Gomez V, Makarić ZL, Marin A, Husa P, Nicolay N, Rose AMC; VEBIS SARI VE network team. Antunes L, et al. Among authors: verdasca n. Influenza Other Respir Viruses. 2025 Mar;19(3):e70081. doi: 10.1111/irv.70081. Influenza Other Respir Viruses. 2025. PMID: 40059069 Free PMC article.
An Overview of Monkeypox Virus Detection in Different Clinical Samples and Analysis of Temporal Viral Load Dynamics.
Cordeiro R, Pelerito A, de Carvalho IL, Lopo S, Neves R, Rocha R, Palminha P, Verdasca N, Palhinhas C, Borrego MJ, Manita C, Ferreira I, Bettencourt C, Vieira P, Silva S, Água-Doce I, Roque C, Cordeiro D, Brondani G, Santos JA, Martins S, Rodrigues I, Ribeiro C, Núncio MS, Gomes JP, Batista FDC. Cordeiro R, et al. Among authors: verdasca n. J Med Virol. 2024 Dec;96(12):e70104. doi: 10.1002/jmv.70104. J Med Virol. 2024. PMID: 39654358 Free PMC article.
COVID-19 Vaccine Effectiveness Against Medically Attended Symptomatic SARS-CoV-2 Infection Among Target Groups in Europe, October 2024-January 2025, VEBIS Primary Care Network.
Laniece Delaunay C, Verdasca N, Monge S, Domegan L, Sève N, Buda S, Meijer A, Lucaccioni H, López Torrijos M, McKenna A, Enouf V, Dürrwald R, In't Velt E, de Valcárcel Laiglesia MÁ, Bennett C, Masse S, Erdwiens A, Hooiveld M, Mlinarić I, Túri G, Rodrigues AP, Martínez-Baz I, Lazar M, Latorre-Margalef N, Borges V, Kaczmarek M, Bacci S, Kissling E; European primary care VE group. Laniece Delaunay C, et al. Among authors: verdasca n. Influenza Other Respir Viruses. 2025 May;19(5):e70120. doi: 10.1111/irv.70120. Influenza Other Respir Viruses. 2025. PMID: 40395132 Free PMC article.
SARS-CoV-2 introductions and early dynamics of the epidemic in Portugal.
Borges V, Isidro J, Trovão NS, Duarte S, Cortes-Martins H, Martiniano H, Gordo I, Leite R, Vieira L; Portuguese network for SARS-CoV-2 genomics (Consortium); Guiomar R, Gomes JP. Borges V, et al. Commun Med (Lond). 2022 Jan 28;2:10. doi: 10.1038/s43856-022-00072-0. eCollection 2022. Commun Med (Lond). 2022. PMID: 35603268 Free PMC article.
Vaccine effectiveness against influenza A in older adults and the effect of chronic conditions: results from the I-MOVE and VEBIS multicentre European hospital case-control studies, 2015/16-2023/24.
Rose AMC, Nicolay N, Mazagatos C, Martínez-Baz I, Launay O, De Mot L, Bella A, Lazar M, Machado A, Kuliešė M, Abela S, Vučina VV, van Gageldonk-Lafeber R, Bino S, Dürrwald R, Paradowska-Stankiewicz I, Horváth JK, Duffy R, Husa P, McMenamin J, Pozo F, Howard J, Latorre-Millán M, Castilla J, Nguyen LBL, Dauby N, Riccardo F, Ivanciuc A, Gomez V, Jančorienė L, Xuereb G, Petrović G, Marbus S, Vasili A, Tolksdorf K, Bogusz J, Oroszi B, Domegan L, Součková L, Marsh K, Bacci S, Kissling E; I-MOVE & VEBIS Hospital Network teams. Rose AMC, et al. BMC Med. 2025 Nov 3;23(1):602. doi: 10.1186/s12916-025-04426-y. BMC Med. 2025. PMID: 41185010 Free PMC article.
Effectiveness of XBB.1.5 Vaccines Against Symptomatic SARS-CoV-2 Infection in Older Adults During the JN.1 Lineage-Predominant Period, European VEBIS Primary Care Multicentre Study, 20 November 2023-1 March 2024.
Merdrignac L, Laniece Delaunay C, Verdasca N, Vega-Piris L, O'Donnell J, Sève N, Trobajo-Sanmartín C, Buda S, Hooiveld M, Rodrigues AP, Túri G, Latorre-Margalef N, Mlinarić I, Lazar M, Maurel M, Castrillejo D, Bennett C, Rameix-Welti MA, Martínez-Baz I, Dürrwald R, Meijer A, Melo A, Oroszi B, Hagey TS, Kurečić Filipović S, Dijkstra F, Gomez V, Bacci S, Kaczmarek M, Kissling E; VEBIS Primary Care Vaccine Effectiveness Group. Merdrignac L, et al. Among authors: verdasca n. Influenza Other Respir Viruses. 2024 Nov;18(11):e70009. doi: 10.1111/irv.70009. Influenza Other Respir Viruses. 2024. PMID: 39523781 Free PMC article.
26 results